+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating treatments for adults with high risk chronic lymphocytic leukemia CLL, a common and aggressive form of leukemia. The study compares a triple drug combination of acalabrutinib, obinutuzumab, and venetoclax GAVe against a dual combination of obinutuzumab and venetoclax GVe. This phase 3 trial aims to see if adding acalabrutinib can prolong the time patients live without disease progression, focusing on patients with specific genetic risk factors like 17p deletion, TP53 mutation, or complex karyotype. Participants receive infusions of obinutuzumab on specific days during the first six cycles, along with oral venetoclax taken daily with increasing doses during the initial cycles and then a fixed dose for up to 12 cycles. Those in the triple combination group also take oral acalabrutinib twice daily for cycles 15 to 24. Treatments are given in cycles lasting several weeks, with precise dosing schedules for each medication. During the study, participants undergo regular assessments including blood tests to monitor disease status and treatment effects. Researchers measure progression-free survival as the primary outcome, along with other outcomes such as minimal residual disease, overall response, survival rates, and time until next treatment. The study involves randomized assignment to treatment groups and continues through multiple cycles, with monitoring extending up to 50 months after the first patient is included.

Age: 18Years - 120YearsAll GendersPhase 3
30 locations
P

Actively Recruiting

This research aims to evaluate the effectiveness of luspatercept in adults with very low, low, or intermediate risk myelodysplastic syndromes MDS who have anemia but do not require blood transfusions and have not been treated with erythropoiesis-stimulating agents ESA. It focuses on patients who are transfusion-independent and have symptomatic anemia, studying the response to treatment in this specific group. All participants receive luspatercept administered as a subcutaneous injection at a dose of 1.75 mg per kg of body weight every 21 days. This treatment continues for 24 weeks initially, and for those who respond by week 25, therapy may extend for up to 1.5 years or until loss of response. This is a single-arm, open-label phase II study without a placebo group. Participants will have assessments at regular intervals, including blood tests and bone marrow sampling, to monitor blood cell counts and treatment response. The main outcome is erythroid response measured after eight treatment cycles each cycle is 21 days. Secondary outcomes include the duration of response, time to response, neutrophil and platelet responses, safety monitoring for adverse effects, and quality of life evaluations using validated questionnaires. The study lasts up to 48 months, including long-term follow-up.

Age: 18Years +All GendersPhase 2
22 locations
P

Actively Recruiting

This research aims to gather detailed data and biomaterials from adults diagnosed with Acute Lymphoblastic Leukemia ALL and related diseases, including certain types of Leukemia and Non-Hodgkins Lymphoma. The registry supports ALL research and quality assurance by collecting information regardless of whether patients participate in clinical trials. The study is observational and involves adults diagnosed and treated under ALL protocols. Participants include adults aged 18 and older with ALL subtypes, other leukemias treated according to ALL protocols, and specific subtypes of Non-Hodgkins Lymphoma treated under B-ALL protocols. The study collects data prospectively on diagnosis, treatment, and outcomes, along with biomaterials related to these conditions. Participants provide information during routine clinical care and follow-up visits for up to 10 years. Data collected includes survival rates, remission status assessed by various methods including PET scans, relapse rates, quality of life questionnaires, and monitoring of toxicities and comorbidities. The study tracks overall survival and other outcomes over long-term follow-up to support research and quality assurance in adult ALL and related diseases.

Age: 18Years +All Genders
147 locations
R

Actively Recruiting

Researchers are conducting a phase 3 clinical trial to assess the effects of adding venetoclax to standard chemotherapy in adults newly diagnosed with acute myeloid leukemia AML or myelodysplastic syndrome with excess blasts-2 MDS-EB-2. The study includes a dose-escalation phase to determine the optimal venetoclax dose before randomizing patients to receive either venetoclax with chemotherapy or placebo with chemotherapy. The goal is to evaluate treatment safety and effectiveness in this patient group. Participants will receive two cycles of induction chemotherapy combined with either venetoclax or placebo. Those who achieve complete remission CR, complete remission with incomplete hematologic recovery CRi, or morphologic leukemia-free state MLFS after induction may continue with consolidation chemotherapy according to standard regimens or investigator choice. Some patients may proceed to allogeneic hematopoietic cell transplantation HCT based on disease characteristics and individual assessment. During the study, participants will be closely monitored through clinical evaluations, including survival rates, remission rates, relapse rates, and quality of life questionnaires. Safety assessments will focus on dose-limiting toxicities during the initial cycles. The study includes long-term follow-up to assess overall survival and event-free survival, with the total duration extending up to approximately ten years after enrollment of the last patient.

Age: 18Years - 75YearsAll GendersPhase 3
91 locations
R

Actively Recruiting

Researchers are conducting a registry study involving adult patients diagnosed with acute myeloid leukemia AML and related myeloid neoplasms, including newly diagnosed or relapsedrefractory cases. The study aims to collect comprehensive data on patient characteristics, family history, biological disease profiles, and clinical outcomes. It also focuses on analyzing disease-related genetic markers and the impact of measurable residual disease MRD using various methods. The study does not involve specific treatments but collects data and biological samples such as bone marrow, blood, plasma, and normal tissue including skin biopsies and other specimens. This observational study enrolls patients from around 80 to 90 sites in Germany and Austria. Patients treatment responses, decisions, and outcomes are tracked over time. Participants are observed for up to 10 years, during which researchers gather information on treatment response, survival, relapse rates, quality of life, and genetic markers. The study includes assessments of event-free survival, relapse-free survival, cumulative incidence of relapse and death, and overall survival. Patient consent is required for registration, data storage, and biobanking of specimens for analysis throughout the observation period.

Age: 18Years +All Genders
94 locations